These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6209508)

  • 21. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
    Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
    Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole-blood assays for evaluation of thromboxane synthase inhibition.
    Spokas EG; Nicholson NS; Suleymanov OD; Walsh GM; Tuffin D
    Methods Mol Biol; 1999; 120():249-56. PubMed ID: 10343321
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacologic effects of Wy 27569: a combined calcium channel blocker and thromboxane synthetase inhibitor.
    Ennis C; Granger SE; Middlefell VC; Philpot ME; Shepperson NB
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):511-9. PubMed ID: 2470986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuation of the development of hypertension in spontaneously hypertensive rats by the thromboxane synthetase inhibitor, 4'-(imidazol-1-yl) acetophenone.
    Uderman HD; Workman RJ; Jackson EK
    Prostaglandins; 1982 Aug; 24(2):237-44. PubMed ID: 6897296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects on prostanoid formation and pharmacokinetics of dazmegrel (UK-38,485), a novel thromboxane synthase inhibitor, in man.
    Lorenz RL; Fischer S; Wober W; Wagner HA; Weber PC
    Biochem Pharmacol; 1986 Mar; 35(5):761-6. PubMed ID: 3513767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
    Yoshida T; Kameda H; Ichikawa Y; Tojo T; Homma M
    J Rheumatol; 1996 Oct; 23(10):1719-24. PubMed ID: 8895147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism.
    Dale J; Thaulow E; Myhre E; Parry J
    Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of OKY-046, a thromboxane synthetase inhibitor, on renal thromboxane synthesis in spontaneously hypertensive rat].
    Nakayama D; Ikeda T
    Nihon Jinzo Gakkai Shi; 1988 Jan; 30(1):79-84. PubMed ID: 3386014
    [No Abstract]   [Full Text] [Related]  

  • 29. Beneficial effects of a new thromboxane synthetase inhibitor in arachidonate-induced sudden death.
    Lefer AM; Okamatsu S; Smith EF; Smith JB
    Thromb Res; 1981 Aug; 23(3):265-73. PubMed ID: 6795758
    [No Abstract]   [Full Text] [Related]  

  • 30. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
    FitzGerald GA; Brash AR; Oates JA; Pedersen AK
    J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thromboxane synthetase inhibition in acute focal cerebral ischemia in cats.
    Moufarrij NA; Little JR; Skrinska V; Lucas FV; Latchaw JP; Slugg RM; Lesser RP
    J Neurosurg; 1984 Dec; 61(6):1107-12. PubMed ID: 6542131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
    Yoshida T; Ichikawa Y; Tojo T; Homma M
    Lupus; 1996 Apr; 5(2):129-38. PubMed ID: 8743126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Roles of vascular and renal thromboxanes in the antihypertensive effects of alpha 1 adrenoceptor antagonists].
    Takada S; Uehara Y; Hirawa N; Numabe A; Yagi S
    Nihon Jinzo Gakkai Shi; 1989 Sep; 31(9):969-75. PubMed ID: 2573747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses.
    Hardee MM; Moore JN; Hardee GE
    Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Attenuation of noradrenergic neurotransmission by the thromboxane synthetase inhibitor, UK 38,485.
    Jackson EK; Uderman HD; Herzer WA; Branch RA
    Life Sci; 1984 Jul; 35(2):221-8. PubMed ID: 6330486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thromboxane synthetase inhibitors in septic shock.
    Short BL; Gardiner WM; Mishik AN; Ramwell PW; Walker D; Fletcher JR
    Adv Shock Res; 1983; 10():143-8. PubMed ID: 6683924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboxane A2 contributes to the enhanced tubuloglomerular feedback activity in young SHR.
    Brännström K; Arendshorst WJ
    Am J Physiol; 1999 May; 276(5):F758-66. PubMed ID: 10330058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of thromboxane synthetase inhibitor on cerebral circulation and metabolism during experimental cerebral ischemia in spontaneously hypertensive rats.
    Sadoshima S; Ooboshi H; Okada Y; Yao H; Ishitsuka T; Fujishima M
    Eur J Pharmacol; 1989 Oct; 169(1):75-83. PubMed ID: 2513212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of thromboxane synthetase potentiates the antihypertensive action of an angiotensin-converting enzyme inhibitor by a prostaglandin-dependent but kinin-independent mechanism.
    Levens NR; Cóte D; Ksander G
    J Pharmacol Exp Ther; 1991 Oct; 259(1):219-27. PubMed ID: 1920118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thromboxane A2 and development of genetic hypertension in the Lyon rat strain.
    Geoffroy J; Benzoni D; Vincent M; Sassard J
    Hypertension; 1990 Dec; 16(6):655-61. PubMed ID: 2147173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.